Long noncoding RNAs and microRNAs in cardiovascular pathophysiology.
Thomas Thum, Gianluigi Condorelli
Author Information
Thomas Thum: From the Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Integrated Research and Treatment Center Transplantation, and REBIRTH Excellence Cluster, Hannover Medical School, Hannover, Germany (T.T.); National Heart and Lung Institute, Imperial College London, London, United Kingdom (T.T.); Humanitas Clinical and Research Center, Rozzano, Milan, Italy (G.C.); Institute of Genetics and Biomedical Research, National Research Country of Italy, Milan, Italy (G.C.); University of Milan, Milan, Italy (G.C.); and Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (G.C.). thum.thomas@mh-hannover.de gianluigi.condorelli@humanitasresearch.it.
Gianluigi Condorelli: From the Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Integrated Research and Treatment Center Transplantation, and REBIRTH Excellence Cluster, Hannover Medical School, Hannover, Germany (T.T.); National Heart and Lung Institute, Imperial College London, London, United Kingdom (T.T.); Humanitas Clinical and Research Center, Rozzano, Milan, Italy (G.C.); Institute of Genetics and Biomedical Research, National Research Country of Italy, Milan, Italy (G.C.); University of Milan, Milan, Italy (G.C.); and Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (G.C.).
RNAs not encoding proteins have gained prominence over the last couple of decades as fundamental regulators of cellular function. Not surprisingly, their dysregulation is increasingly being linked to pathology. Here, we review recent reports investigating the pathophysiological relevance of this species of RNA for the cardiovascular system, concentrating mainly on recent findings on long noncoding RNAs and microRNAs in cardiac hypertrophy and failure.
